Difference between revisions of "Endometrial hyperplasia"
m (→WHO system) |
|||
(60 intermediate revisions by the same user not shown) | |||
Line 1: | Line 1: | ||
:''See [[Endometrium]] for | :''See [[Endometrium]] for an introduction to the topic.'' | ||
'''Endometrial hyperplasia''', abbreviated '''EH''', is a precursor to [[endometrial carcinoma]]. | '''Endometrial hyperplasia''', abbreviated '''EH''', is a precursor to [[endometrial carcinoma]]. | ||
=Overview= | |||
===WHO endometrial hyperplasia classification of 2014=== | |||
The 2014 WHO system has two categories:<ref name=pmid25797956 >{{Cite journal | last1 = Emons | first1 = G. | last2 = Beckmann | first2 = MW. | last3 = Schmidt | first3 = D. | last4 = Mallmann | first4 = P. | title = New WHO Classification of Endometrial Hyperplasias. | journal = Geburtshilfe Frauenheilkd | volume = 75 | issue = 2 | pages = 135-136 | month = Feb | year = 2015 | doi = 10.1055/s-0034-1396256 | PMID = 25797956 }}</ref> | |||
*Hyperplasia without atypia. | |||
*Atypical hyperplasia/endometrioid intraepithelial neoplasia. | |||
==WHO system== | ===WHO endometrial hyperplasia classification of 1994=== | ||
=== | The 1994 WHO system is based on determining:<ref name=pmid25797956>{{Cite journal | last1 = Emons | first1 = G. | last2 = Beckmann | first2 = MW. | last3 = Schmidt | first3 = D. | last4 = Mallmann | first4 = P. | title = New WHO Classification of Endometrial Hyperplasias. | journal = Geburtshilfe Frauenheilkd | volume = 75 | issue = 2 | pages = 135-136 | month = Feb | year = 2015 | doi = 10.1055/s-0034-1396256 | PMID = 25797956 }}</ref> | ||
# Gland density (normal/low = ''simple hyperplasia'', high density = ''complex hyperplasia''). | |||
# Presence/absence of nuclear atypia. | |||
It consists of four categories: | |||
*[[Simple endometrial hyperplasia]]. | |||
* | *[[Simple endometrial hyperplasia with atypia]]. | ||
* | *[[Complex endometrial hyperplasia]]. | ||
* | *[[Complex endometrial hyperplasia with atypia]]. | ||
* | |||
===Alternate classifications - overview=== | |||
Two alternative grading systems exist, that are (currently) not widely used:<ref name=pmid11764378>{{Cite journal | last1 = Dietel | first1 = M. | title = The histological diagnosis of endometrial hyperplasia. Is there a need to simplify? | journal = Virchows Arch | volume = 439 | issue = 5 | pages = 604-8 | month = Nov | year = 2001 | doi = | PMID = 11764378 }}</ref> | |||
#European group of experts (1999). | |||
#Endometrial collaborative group/Harvard (2000). | |||
Both consist of two categories, as opposed to four found in the WHO classification. | |||
== | ====European group of experts classification==== | ||
#Endometrial hyperplasia. | |||
#Endometrioid neoplasia. | |||
====Endometrial collaborative group/Harvard classification==== | |||
#Endometrial hyperplasia. | |||
#Endometrial intraepithelial neoplasia (EIN). | |||
==Management of endometrial hyperplasia== | ==WHO classification of 1994== | ||
*Endometrial hyperplasia with atypia is usually treated with hysterectomy.<ref>[http://www.aafp.org/afp/990600ap/3069.html http://www.aafp.org/afp/990600ap/3069.html]</ref> | ===Management of endometrial hyperplasia=== | ||
**In women who want to maintain fertility it may be treated with progestin + short interval re-biopsies (q3 months).<ref>[http://www.aafp.org/afp/20060801/practice.html http://www.aafp.org/afp/20060801/practice.html]</ref> | *Endometrial hyperplasia with atypia is usually treated with hysterectomy.<ref>URL: [http://www.aafp.org/afp/990600ap/3069.html http://www.aafp.org/afp/990600ap/3069.html].</ref> | ||
**In women who want to maintain fertility it may be treated with progestin + short interval re-biopsies (q3 months).<ref>URL: [http://www.aafp.org/afp/20060801/practice.html http://www.aafp.org/afp/20060801/practice.html].</ref> | |||
*Endometrial hyperplasia without atypia is treated by: | *Endometrial hyperplasia without atypia is treated by: | ||
**Progestins + close follow-up ''OR'' hysterectomy. | **Progestins + close follow-up ''OR'' hysterectomy. | ||
===Risk of progression to carcinoma as per 1994 system=== | |||
Approximate risk of progression to [[endometrial carcinoma]] - Latta rule of 3s:<ref>Latta, E. January 2009.</ref> | |||
===Risk of progression to carcinoma=== | |||
Approximate risk of progression to carcinoma:<ref> | |||
{| class="wikitable" | {| class="wikitable" | ||
| || '''Simple''' || '''Complex''' | | || '''Simple''' || '''Complex''' | ||
Line 61: | Line 48: | ||
| Without atypia || 1% || 3% | | Without atypia || 1% || 3% | ||
|- | |- | ||
| With atypia || 9% || 27% | | With atypia || 9% † || 27% ‡ | ||
|- | |- | ||
|} | |} | ||
==See also | Notes: | ||
* † 8% is the true number.<ref name=pmid4005805>{{Cite journal | last1 = Kurman | first1 = RJ. | last2 = Kaminski | first2 = PF. | last3 = Norris | first3 = HJ. | title = The behavior of endometrial hyperplasia. A long-term study of untreated hyperplasia in 170 patients. | journal = Cancer | volume = 56 | issue = 2 | pages = 403-12 | month = Jul | year = 1985 | doi = | PMID = 4005805 }}</ref> | |||
* ‡ 29% is the true number.<ref name=pmid4005805/> | |||
===Ki-67=== | |||
There is one paper that looks at Ki-67:<ref>{{Cite journal | last1 = Abike | first1 = F. | last2 = Tapisiz | first2 = OL. | last3 = Zergeroglu | first3 = S. | last4 = Dunder | first4 = I. | last5 = Temizkan | first5 = O. | last6 = Temizkan | first6 = I. | last7 = Payasli | first7 = A. | title = PCNA and Ki-67 in endometrial hyperplasias and evaluation of the potential of malignancy. | journal = Eur J Gynaecol Oncol | volume = 32 | issue = 1 | pages = 77-80 | month = | year = 2011 | doi = | PMID = 21446331 }}</ref> | |||
{| class="wikitable sortable" | |||
! Diagnosis | |||
! Percent positive | |||
|- | |||
| [[Secretory phase endometrium]] | |||
| <center>15%</center> | |||
|- | |||
| [[Proliferative phase endometrium]] | |||
| <center>42%</center> | |||
|- | |||
| [[Simple endometrial hyperplasia|Simple hyperplasia]] | |||
| <center>26%</center> | |||
|- | |||
| [[Simple endometrial hyperplasia with atypia|Simple hyperplasia with atypia]] | |||
| <center>23%</center> | |||
|- | |||
| [[Complex endometrial hyperplasia|Complex hyperplasia]] | |||
| <center>16%</center> | |||
|- | |||
| [[Complex endometrial hyperplasia with atypia|Complex hyperplasia with atypia]] | |||
| <center>42%</center> | |||
|} | |||
==WHO system of 1994 - detail articles== | |||
Almost all hyperplasia is seen in the context of proliferative-type endometrium. [[Endometrial hyperplasia with secretory changes|Hyperplasia in the secretory-type endometrium]] is extremely rare and something diagnosed by or in consultation with an expert in gynecologic pathology. | |||
===Simple endometrial hyperplasia=== | |||
*[[AKA]] ''simple hyperplasia''. | |||
{{Main|Simple endometrial hyperplasia}} | |||
===Simple endometrial hyperplasia with atypia=== | |||
{{Main|Simple endometrial hyperplasia}} | |||
===Complex endometrial hyperplasia=== | |||
*Abbreviated ''CEH''. | |||
{{Main|Complex endometrial hyperplasia}} | |||
===Complex endometrial hyperplasia with atypia=== | |||
*[[AKA]] ''complex atypical hyperplasia''. | |||
{{Main|Complex endometrial hyperplasia}} | |||
=Other= | |||
==Endometrial hyperplasia with secretory changes== | |||
===General=== | |||
*Rare. | |||
*Secretory changes seen in 1-2% of endometrial hyperplasias/endometrial carcinomas.<ref>Simon RA, Hansen K, Xiong JJ, et al. [http://www.abstracts2view.com/uscap12/view.php?nu=USCAP12L_1248 PTEN status and frequency of endometrial carcinoma and its precursors arising in functional secretory endometrium; an immunohistochemical study of 29 cases]. Mod Pathol. 2012;25(Suppl 2): 1248A.</ref> | |||
===Microscopic=== | |||
Features:<ref>Simon RA. [http://www.cap.org/apps/cap.portal?_nfpb=true&cntvwrPtlt_actionOverride=%2Fportlets%2FcontentViewer%2Fshow&_windowLabel=cntvwrPtlt&cntvwrPtlt%7BactionForm.contentReference%7D=cap_today%2F0612%2F0612_qa.html CAP Today]. June 2012. Accessed on: 24 April 2013.</ref> | |||
*Secretory changes - includes at least one of three following:<ref name=pmid12648591>{{Cite journal | last1 = Tresserra | first1 = F. | last2 = Lopez-Yarto | first2 = M. | last3 = Grases | first3 = PJ. | last4 = Ubeda | first4 = A. | last5 = Pascual | first5 = MA. | last6 = Labastida | first6 = R. | title = Endometrial hyperplasia with secretory changes. | journal = Gynecol Oncol | volume = 88 | issue = 3 | pages = 386-93 | month = Mar | year = 2003 | doi = | PMID = 12648591 }}</ref> | |||
*#Stromal decidualization. | |||
*#Cytoplasmic vacuolization. | |||
*#Intraluminal secretions. | |||
*Proliferative-type epithelium. † | |||
**Mitoses. | |||
**Nuclear atypia. | |||
**Pseudostratified epithelium. | |||
Notes: | |||
* † This is ''not'' precisely defined. I suppose it is some of the things Bell and Ostrezega<ref name=pmid3610133/> mention (mitoses, nuclear atypia, pseudostratified epithelium). | |||
**Bell and Ostrezega<ref name=pmid3610133>{{Cite journal | last1 = Bell | first1 = CD. | last2 = Ostrezega | first2 = E. | title = The significance of secretory features and coincident hyperplastic changes in endometrial biopsy specimens. | journal = Hum Pathol | volume = 18 | issue = 8 | pages = 830-8 | month = Aug | year = 1987 | doi = | PMID = 3610133 }}</ref> give a laundry list for differentiating ''benign secretory endometrium'' from ''hyperplasia with secretory changes'': focal architectural abnormalities, metaplastic ciliated & "clear" cells, sharp luminal border, epithelial pseudopalisading, nuclear atypia, vesicular nuclei, mitoses. | |||
DDx: | |||
*[[Secretory phase endometrium]]. | |||
*[[Endometrium with hormonal changes]]. | |||
Images: | |||
*[http://www.cap.org/apps/docs/cap_today/0612/0612a_qa.pdf Endometrial hyperplasia with secretory changes (cap.org)]. | |||
=See also= | |||
*[[Endometrium]]. | *[[Endometrium]]. | ||
*[[Endometrial carcinoma]]. | |||
*[[Gynecologic pathology]]. | *[[Gynecologic pathology]]. | ||
=References= | |||
{{reflist|2}} | {{reflist|2}} | ||
[[Category:Gynecologic pathology]] | [[Category:Gynecologic pathology]] |
Latest revision as of 15:42, 27 June 2016
- See Endometrium for an introduction to the topic.
Endometrial hyperplasia, abbreviated EH, is a precursor to endometrial carcinoma.
Overview
WHO endometrial hyperplasia classification of 2014
The 2014 WHO system has two categories:[1]
- Hyperplasia without atypia.
- Atypical hyperplasia/endometrioid intraepithelial neoplasia.
WHO endometrial hyperplasia classification of 1994
The 1994 WHO system is based on determining:[1]
- Gland density (normal/low = simple hyperplasia, high density = complex hyperplasia).
- Presence/absence of nuclear atypia.
It consists of four categories:
- Simple endometrial hyperplasia.
- Simple endometrial hyperplasia with atypia.
- Complex endometrial hyperplasia.
- Complex endometrial hyperplasia with atypia.
Alternate classifications - overview
Two alternative grading systems exist, that are (currently) not widely used:[2]
- European group of experts (1999).
- Endometrial collaborative group/Harvard (2000).
Both consist of two categories, as opposed to four found in the WHO classification.
European group of experts classification
- Endometrial hyperplasia.
- Endometrioid neoplasia.
Endometrial collaborative group/Harvard classification
- Endometrial hyperplasia.
- Endometrial intraepithelial neoplasia (EIN).
WHO classification of 1994
Management of endometrial hyperplasia
- Endometrial hyperplasia with atypia is usually treated with hysterectomy.[3]
- In women who want to maintain fertility it may be treated with progestin + short interval re-biopsies (q3 months).[4]
- Endometrial hyperplasia without atypia is treated by:
- Progestins + close follow-up OR hysterectomy.
Risk of progression to carcinoma as per 1994 system
Approximate risk of progression to endometrial carcinoma - Latta rule of 3s:[5]
Simple | Complex | |
Without atypia | 1% | 3% |
With atypia | 9% † | 27% ‡ |
Notes:
Ki-67
There is one paper that looks at Ki-67:[7]
Diagnosis | Percent positive |
---|---|
Secretory phase endometrium | |
Proliferative phase endometrium | |
Simple hyperplasia | |
Simple hyperplasia with atypia | |
Complex hyperplasia | |
Complex hyperplasia with atypia |
WHO system of 1994 - detail articles
Almost all hyperplasia is seen in the context of proliferative-type endometrium. Hyperplasia in the secretory-type endometrium is extremely rare and something diagnosed by or in consultation with an expert in gynecologic pathology.
Simple endometrial hyperplasia
- AKA simple hyperplasia.
Simple endometrial hyperplasia with atypia
Complex endometrial hyperplasia
- Abbreviated CEH.
Complex endometrial hyperplasia with atypia
- AKA complex atypical hyperplasia.
Other
Endometrial hyperplasia with secretory changes
General
- Rare.
- Secretory changes seen in 1-2% of endometrial hyperplasias/endometrial carcinomas.[8]
Microscopic
Features:[9]
- Secretory changes - includes at least one of three following:[10]
- Stromal decidualization.
- Cytoplasmic vacuolization.
- Intraluminal secretions.
- Proliferative-type epithelium. †
- Mitoses.
- Nuclear atypia.
- Pseudostratified epithelium.
Notes:
- † This is not precisely defined. I suppose it is some of the things Bell and Ostrezega[11] mention (mitoses, nuclear atypia, pseudostratified epithelium).
- Bell and Ostrezega[11] give a laundry list for differentiating benign secretory endometrium from hyperplasia with secretory changes: focal architectural abnormalities, metaplastic ciliated & "clear" cells, sharp luminal border, epithelial pseudopalisading, nuclear atypia, vesicular nuclei, mitoses.
DDx:
Images:
See also
References
- ↑ 1.0 1.1 Emons, G.; Beckmann, MW.; Schmidt, D.; Mallmann, P. (Feb 2015). "New WHO Classification of Endometrial Hyperplasias.". Geburtshilfe Frauenheilkd 75 (2): 135-136. doi:10.1055/s-0034-1396256. PMID 25797956.
- ↑ Dietel, M. (Nov 2001). "The histological diagnosis of endometrial hyperplasia. Is there a need to simplify?". Virchows Arch 439 (5): 604-8. PMID 11764378.
- ↑ URL: http://www.aafp.org/afp/990600ap/3069.html.
- ↑ URL: http://www.aafp.org/afp/20060801/practice.html.
- ↑ Latta, E. January 2009.
- ↑ 6.0 6.1 Kurman, RJ.; Kaminski, PF.; Norris, HJ. (Jul 1985). "The behavior of endometrial hyperplasia. A long-term study of untreated hyperplasia in 170 patients.". Cancer 56 (2): 403-12. PMID 4005805.
- ↑ Abike, F.; Tapisiz, OL.; Zergeroglu, S.; Dunder, I.; Temizkan, O.; Temizkan, I.; Payasli, A. (2011). "PCNA and Ki-67 in endometrial hyperplasias and evaluation of the potential of malignancy.". Eur J Gynaecol Oncol 32 (1): 77-80. PMID 21446331.
- ↑ Simon RA, Hansen K, Xiong JJ, et al. PTEN status and frequency of endometrial carcinoma and its precursors arising in functional secretory endometrium; an immunohistochemical study of 29 cases. Mod Pathol. 2012;25(Suppl 2): 1248A.
- ↑ Simon RA. CAP Today. June 2012. Accessed on: 24 April 2013.
- ↑ Tresserra, F.; Lopez-Yarto, M.; Grases, PJ.; Ubeda, A.; Pascual, MA.; Labastida, R. (Mar 2003). "Endometrial hyperplasia with secretory changes.". Gynecol Oncol 88 (3): 386-93. PMID 12648591.
- ↑ 11.0 11.1 Bell, CD.; Ostrezega, E. (Aug 1987). "The significance of secretory features and coincident hyperplastic changes in endometrial biopsy specimens.". Hum Pathol 18 (8): 830-8. PMID 3610133.